USPTO serial 79313063
FKB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 9, 2022
- Examiner
- KAPLAN, VALERIE ELIZABETH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with FKB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
JP
Other trademarks owned by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
JP
Other trademarks owned by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
JP
Other trademarks owned by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kaushal Odedra
Kaushal Odedra ODEDRA LAW OFFICE, PLLC2020 Pennsylvania Ave, NW, #152Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases; pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases; pharmaceutical preparations for use in connection with humans for the treatment of parasitic diseases; pharmaceutical preparations for use in connection with humans for the prevention of parasitic diseases; pharmaceutical preparations for use in connection with humans for the treatment of neoplasms; pharmaceutical preparations for use in connection with humans for the prevention of neoplasms; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the blood; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the blood; pharmaceutical preparations for use in connection with humans for the treatment of diseases of blood-forming organs; pharmaceutical preparations for use in connection with humans for the prevention of diseases of blood-forming organs; pharmaceutical preparations for use in connection with humans for the treatment of diseases of certain disorders involving the immune mechanism; pharmaceutical preparations for use in connection with humans for the prevention of diseases of certain disorders involving the immune mechanism; pharmaceutical preparations for use in connection with humans for the treatment of endocrine diseases; pharmaceutical preparations for use in connection with humans for the prevention of endocrine diseases; pharmaceutical preparations for use in connection with humans for the treatment of nutritional diseases; pharmaceutical preparations for use in connection with humans for the prevention of nutritional diseases; pharmaceutical preparations for use in connection with humans for the treatment of metabolic diseases; pharmaceutical preparations for use in connection with humans for the prevention of metabolic diseases; pharmaceutical preparations for use in connection with humans for the treatment of mental disorders; pharmaceutical preparations for use in connection with humans for the prevention of mental disorders; pharmaceutical preparations for use in connection with humans for the treatment of behavioural disorders; pharmaceutical preparations for use in connection with humans for the prevention of behavioural disorders; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the nervous system; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the nervous system; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the eye; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the eye; pharmaceutical preparations for use in connection with humans for the treatment of diseases of eye adnexa; pharmaceutical preparations for use in connection with humans for the prevention of diseases of eye adnexa; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the ear; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the ear; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the mastoid process; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the mastoid process; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the circulatory system; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the circulatory system; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the respiratory system; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the respiratory system; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the digestive system; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the digestive system; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the skin; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the skin; pharmaceutical preparations for use in connection with humans for the treatment of diseases of subcutaneous tissue; pharmaceutical preparations for use in connection with humans for the prevention of diseases of subcutaneous tissue; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the musculoskeletal system pharmaceutical preparations for use in connection with humans for the prevention of diseases of the musculoskeletal system; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the connective tissue; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the connective tissue; pharmaceutical preparations for use in connection with humans for the treatment of diseases of the genitourinary system; pharmaceutical preparations for use in connection with humans for the prevention of diseases of the genitourinary system; pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases and diabetes occurred in pregnancy; pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases and diabetes occurred in pregnancy; pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases occurred in childbirth; pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases occurred in childbirth; pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases occurred in the puerperium; pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases occurred in the puerperium; pharmaceutical preparations for use in connection with humans for the treatment of nutritional deficiency conditions originating in the perinatal period; pharmaceutical preparations for use in connection with humans for the prevention of nutritional deficiency conditions originating in the perinatal period; pharmaceutical preparations for use in connection with humans for the treatment of congenital malformations; pharmaceutical preparations for use in connection with humans for the prevention of congenital malformations; pharmaceutical preparations for use in connection with humans for the treatment of deformations; pharmaceutical preparations for use in connection with humans for the prevention of deformations; pharmaceutical preparations for use in connection with humans for the treatment of chromosomal abnormalities; pharmaceutical preparations for use in connection with humans for the prevention of chromosomal abnormalities; prescribed pharmaceutical preparations for the treatment of infectious diseases; prescribed pharmaceutical preparations for the prevention of infectious diseases; prescribed pharmaceutical preparations for the treatment of parasitic diseases; prescribed pharmaceutical preparations for the prevention of parasitic diseases; prescribed pharmaceutical preparations for the treatment of neoplasms; prescribed pharmaceutical preparations for the prevention of neoplasms; prescribed pharmaceutical preparations for the treatment of diseases of the blood; prescribed pharmaceutical preparations for the prevention of diseases of the blood prescribed pharmaceutical preparations for the treatment of diseases of blood-forming organs; prescribed pharmaceutical preparations for the prevention of diseases of blood-forming organs; prescribed pharmaceutical preparations for the treatment of diseases of certain disorders involving the immune mechanism; prescribed pharmaceutical preparations for the prevention of diseases of certain disorders involving the immune mechanism; prescribed pharmaceutical preparations for the treatment of endocrine diseases; prescribed pharmaceutical preparations for the prevention of endocrine diseases; prescribed pharmaceutical preparations for the treatment of nutritional diseases; prescribed pharmaceutical preparations for the prevention of nutritional diseases; prescribed pharmaceutical preparations for the treatment of metabolic diseases; prescribed pharmaceutical preparations for the prevention of metabolic diseases; prescribed pharmaceutical preparations for the treatment of mental disorders; prescribed pharmaceutical preparations for the prevention of mental disorders; prescribed pharmaceutical preparations for the treatment of behavioural disorders; prescribed pharmaceutical preparations for the prevention of behavioural disorders; prescribed pharmaceutical preparations for the treatment of diseases of the nervous system; prescribed pharmaceutical preparations for the prevention of diseases of the nervous system; prescribed pharmaceutical preparations for the treatment of diseases of the eye; prescribed pharmaceutical preparations for the prevention of diseases of the eye; prescribed pharmaceutical preparations for the treatment of diseases of eye adnexa; prescribed pharmaceutical preparations for the prevention of diseases of eye adnexa; prescribed pharmaceutical preparations for the treatment of diseases of the ear; prescribed pharmaceutical preparations for the prevention of diseases of the ear; prescribed pharmaceutical preparations for the treatment of diseases of the mastoid process; prescribed pharmaceutical preparations for the prevention of diseases of the mastoid process; prescribed pharmaceutical preparations for the treatment of diseases of the circulatory system; prescribed pharmaceutical preparations for the prevention of diseases of the circulatory system; prescribed pharmaceutical preparations for the treatment of diseases of the respiratory system; prescribed pharmaceutical preparations for the prevention of diseases of the respiratory system; prescribed pharmaceutical preparations for the treatment of diseases of the digestive system; prescribed pharmaceutical preparations for the prevention of diseases of the digestive system; prescribed pharmaceutical preparations for the treatment of diseases of the skin; prescribed pharmaceutical preparations for the prevention of diseases of the skin; prescribed pharmaceutical preparations for the treatment of diseases of subcutaneous tissue; prescribed pharmaceutical preparations for the prevention of diseases of subcutaneous tissue; prescribed pharmaceutical preparations for the treatment of diseases of the musculoskeletal system; prescribed pharmaceutical preparations for the prevention of diseases of the musculoskeletal system; prescribed pharmaceutical preparations for the treatment of diseases of the connective tissue; prescribed pharmaceutical preparations for the prevention of diseases of the connective tissue; prescribed pharmaceutical preparations for the treatment of diseases of the genitourinary system; prescribed pharmaceutical preparations for the prevention of diseases of the genitourinary system; prescribed pharmaceutical preparations for the treatment of infectious diseases and diabetes occurred in pregnancy; prescribed pharmaceutical preparations for the prevention of infectious diseases and diabetes occurred in pregnancy; prescribed pharmaceutical preparations for the treatment of infectious diseases occurred in childbirth; prescribed pharmaceutical preparations for the prevention of infectious diseases occurred in childbirth; prescribed pharmaceutical preparations for the treatment of infectious diseases occurred in the puerperium; prescribed pharmaceutical preparations for the prevention of infectious diseases occurred in the puerperium; prescribed pharmaceutical preparations for the treatment of nutritional deficiency conditions originating in the perinatal period; prescribed pharmaceutical preparations for the prevention of nutritional deficiency conditions originating in the perinatal period; prescribed pharmaceutical preparations for the treatment of congenital malformations; prescribed pharmaceutical preparations for the prevention of congenital malformations; prescribed pharmaceutical preparations for the treatment of deformations; prescribed pharmaceutical preparations for the prevention of deformations; prescribed pharmaceutical preparations for the treatment of chromosomal abnormalities; prescribed pharmaceutical preparations for the prevention of chromosomal abnormalities; biological pharmaceutical preparations for the treatment of infectious diseases; biological pharmaceutical preparations for the prevention of infectious diseases; biological pharmaceutical preparations for the treatment of parasitic diseases; biological pharmaceutical preparations for the prevention of parasitic diseases; biological pharmaceutical preparations for the treatment of neoplasms; biological pharmaceutical preparations for the prevention of neoplasms; biological pharmaceutical preparations for the treatment of diseases of the blood; biological pharmaceutical preparations for the prevention of diseases of the blood; biological pharmaceutical preparations for the treatment of diseases of blood-forming organs; biological pharmaceutical preparations for the prevention of diseases of blood-forming organs; biological pharmaceutical preparations for the treatment of diseases of certain disorders involving the immune mechanism; biological pharmaceutical preparations for the prevention of diseases of certain disorders involving the immune mechanism; biological pharmaceutical preparations for the treatment of endocrine diseases; biological pharmaceutical preparations for the prevention of endocrine diseases; biological pharmaceutical preparations for the treatment of nutritional diseases; biological pharmaceutical preparations for the prevention of nutritional diseases; biological pharmaceutical preparations for the treatment of metabolic diseases; biological pharmaceutical preparations for the prevention of metabolic diseases; biological pharmaceutical preparations for the treatment of mental disorders; biological pharmaceutical preparations for the prevention of mental disorders; biological pharmaceutical preparations for the treatment of behavioural disorders; biological pharmaceutical preparations for the prevention of behavioural disorders; biological pharmaceutical preparations for the treatment of diseases of the nervous system; biological pharmaceutical preparations for the prevention of diseases of the nervous system; biological pharmaceutical preparations for the treatment of diseases of the eye; biological pharmaceutical preparations for the prevention of diseases of the eye; biological pharmaceutical preparations for the treatment of diseases of eye adnexa; biological pharmaceutical preparations for the prevention of diseases of eye adnexa; biological pharmaceutical preparations for the treatment of diseases of the ear; biological pharmaceutical preparations for the prevention of diseases of the ear; biological pharmaceutical preparations for the treatment of diseases of the mastoid process; biological pharmaceutical preparations for the prevention of diseases of the mastoid process; biological pharmaceutical preparations for the treatment of diseases of the circulatory system; biological pharmaceutical preparations for the prevention of diseases of the circulatory system; biological pharmaceutical preparations for the treatment of diseases of the respiratory system; biological pharmaceutical preparations for the prevention of diseases of the respiratory system; biological pharmaceutical preparations for the treatment of diseases of the digestive system; biological pharmaceutical preparations for the prevention of diseases of the digestive system; biological pharmaceutical preparations for the treatment of diseases of the skin; biological pharmaceutical preparations for the prevention of diseases of the skin; biological pharmaceutical preparations for the treatment of diseases of subcutaneous tissue; biological pharmaceutical preparations for the prevention of diseases of subcutaneous tissue; biological pharmaceutical preparations for the treatment of diseases of the musculoskeletal system; biological pharmaceutical preparations for the prevention of diseases of the musculoskeletal system; biological pharmaceutical preparations for the treatment of diseases of the connective tissue; biological pharmaceutical preparations for the prevention of diseases of the connective tissue; biological pharmaceutical preparations for the treatment of diseases of the genitourinary system; biological pharmaceutical preparations for the prevention of diseases of the genitourinary system; biological pharmaceutical preparations for the treatment of infectious diseases and diabetes occurred in pregnancy; biological pharmaceutical preparations for the prevention of infectious diseases and diabetes occurred in pregnancy; biological pharmaceutical preparations for the treatment of infectious diseases occurred in childbirth; biological pharmaceutical preparations for the prevention of infectious diseases occurred in childbirth; biological pharmaceutical preparations for the treatment of infectious diseases occurred in the puerperium; biological pharmaceutical preparations for the prevention of infectious diseases occurred in the puerperium; biological pharmaceutical preparations for the treatment of nutritional deficiency conditions originating in the perinatal period; biological pharmaceutical preparations for the prevention of nutritional deficiency conditions originating in the perinatal period; biological pharmaceutical preparations for the treatment of congenital malformations; biological pharmaceutical preparations for the prevention of congenital malformations; biological pharmaceutical preparations for the treatment of deformations; biological pharmaceutical preparations for the prevention of deformations; biological pharmaceutical preparations for the treatment of chromosomal abnormalities; biological pharmaceutical preparations for the prevention of chromosomal abnormalities; bandages for dressings | ACTIVE | — |
| 010 | Apparatus for drug administration, namely, drug delivery systems, comprised of injector, and autoinjector, both sold empty; therapeutic inhalers, sold empty; high frequency electromagnetic therapy apparatus; oxygen inhalers for therapeutic purposes sold empty; ultraviolet radiator units for therapeutic purposes; defibrillators; pneumothorax apparatus, namely, medical apparatus for diagnosing or treating respiratory conditions; heart pacemakers; mercury arc lamp units for therapeutic purposes; infrared radiator units for therapeutic purposes; puncture apparatus for therapeutic purposes, namely, medical devices for closing wounds; lavage apparatus for therapeutic purposes, namely, apparatus for washing out body cavities; carbon arc lamp units for therapeutic purposes; injection syringes, syringe barrels; injection needles; infusion apparatus for therapeutic purposes, namely, infusion pumps for delivering measured amounts of solutions into the bloodstream over rime; ultrasonic therapy machines and apparatus; short wave therapy machines and apparatus; therapeutic bath apparatus and instruments, namely, appliances for washing body cavities; massage apparatus for medical purposes; low frequency electric therapy apparatus; static electric therapy apparatus; dialyzers, namely, blood component separation apparatus for medical purposes; acupuncture needles; sprayers for medical purposes, namely, drug delivery sprayers sold empty; suture apparatus for medical purposes, namely, suture needles and suture materials; radioisotope therapy apparatus and instruments; incubators for babies; blood transfusion apparatus; containers and trays specially designed for transporting and holding pharmaceuticals; injection device for pharmaceuticals; injection instruments without needles; injection instruments with needles | ACTIVE | — |
| 035 | Providing information concerning commercial sales in the field of pharmaceuticals | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals | ACTIVE | — |
| 042 | Pharmaceutical research; pharmaceutical development | ACTIVE | — |
| 044 | Pharmaceutical information services provided via the Internet, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical information services provided via the Internet; providing medical information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- Other trademarks owned by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- Other trademarks owned by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named FKB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 6, 2023 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jan 15, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 18, 2022 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Nov 18, 2022 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Nov 9, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 9, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 9, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 30, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 24, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 24, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 4, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 4, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 4, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 18, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 18, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 18, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 18, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 21, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 23, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 23, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 29, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 28, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 14, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 29, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 25, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 21, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jun 11, 2021 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |